Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling-Reference-Cited by-同舟云学术

Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling

Published:2017-04-25 Issue:9 Volume:44 Page:e226-e227
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Furudate Sadanori¹,Fujimura Taku¹^ORCID,Kambayashi Yumi¹,Hidaka Takanori¹,Sato Yota¹,Tanita Kayo¹,Hashimoto Akira¹,Aiba Setsuya¹

Affiliation:

1. Department of Dermatology; Tohoku University Graduate School of Medicine; Sendai Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.13898/fullpdf

Reference5 articles.

1. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Ascierto;Lancet Oncol,2016

2. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations;Yamazaki;J Dermatol,2015

3. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways;Macdonald;J Am Acad Dermatol,2015

4. Prolactin enhances basal and IL-17-induced CCL20 production by human keratinocytes;Kanda;Eur J Immunol,2009

5. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis;Wu;J Exp Med,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center;The Journal of Dermatology;2021-04-20

2. Severe pyrexia from nivolumab‐resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib;The Journal of Dermatology;2020-04-15

3. Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside;Cancers;2019-09-11

4. Three cases of nivolumab therapy‐failed advanced melanoma successfully controlled by ipilimumab with intensity‐modulated radiotherapy;The Journal of Dermatology;2019-03-25

5. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials;Expert Opinion on Investigational Drugs;2018-12-16